Table I. Selection of phase II studies of monochemotherapy in advanced biliary tract cancer.
| Location | n | Response rate (%) | Progression free survival (months) | Overall survival (months) | |
|---|---|---|---|---|---|
| 5-Fluorouracil/folinic acid | |||||
| Chen et al. 1998 7 | Cholangiocarcinoma | 13 | 33 | 4 | 7 |
| Gallbladder | 6 | ||||
| Choi et al. 2000 8 | Biliary tract | 28 | 32 | NR | 6 |
| Gemcitabine | |||||
| Kubicka et al. 2001 9 | Cholangiocarcinoma | 23 | 30 | NR | NR |
| HCC | 20 | 5 | NR | NR | |
| Gallardo et al. 2001 10 | Gallbladder | 26 | 35 | NR | 7.5 |
| Park et al. 2005 11 | Cholangiocarcinoma | 15 | 26.1 | 8.1 | 13.1 |
| Gallbladder | 8 | ||||
| S1 (oral fluoropyrimidine derivative) | |||||
| Ueno et al. 2004 12 | Gallbladder | 16 | 21.1 | 3.7 | 8.3 |
| Cholangiocarcinoma | 3 | ||||
NR: not reported; HCC: hepatocellular carcinoma.